Caris Life Sciences, Inc. 4

Director Jonathan Kenneth Charles Knowles received 1,600 shares of Caris Life Sciences, Inc. common stock as stock compensation in lieu of cash for 2026 board retainer fees.

On May 29, 2026, director Jonathan Kenneth Charles Knowles received 1,600 shares of Caris Life Sciences, Inc. common stock at an implied price of $15.62 per share, issued in lieu of cash compensation for his 2026 board retainer fees. This equity award, valued at approximately $24,992, increased his direct beneficial ownership to 308,979 shares. The shares were calculated based on the ten trading day average daily volume-weighted average price through and including May 29, 2026, indicating a routine, formula-based director compensation grant rather than an open-market purchase or sale.

Filing Facts

CIK

2019410

Ticker

CAI

Form

4

Source Type

sec

Accession

0001662103-26-000002

Alert Tier

5